Images List Premium Download Classic

Proliferative

Proliferative-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis
June 22, 2017 - N°20170176434

Provided herein are methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis and other proteinuric renal diseases such as native fsgs, minimal change disease, glomerular nephritis, membrano-proliferative glomerular nephritis (membranous), or iga glomerular nephritis (membranous).
NEW Peptide inhibitors of bcr-abl oligomerization
University Of Utah Research Foundation
June 22, 2017 - N°20170174750

In one aspect, the invention relates to peptides comprising the bcr-abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the bcr-abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with bcr-abl using the compounds and compositions. ...
NEW Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
Capella Therapeutics, Inc.
June 22, 2017 - N°20170174697

Provided herein are benzimidazole derivatives, for example, of formula (i), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
NEW Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Combination therapy for ameliorating adverse side effects caused by chemotherapy
Yeastern Biotech Co., Ltd
June 22, 2017 - N°20170173110

The invention generally relates to an immunomodulatory protein and a chemotherapeutic agent for simultaneous, contemporaneous or sequential use in the treatment of diseases, more particularly of proliferative diseases, still more particularly of cancer(s), to a combination of an fip and a chemotherapeutic agent, as well as to the medical and biotechnological applications thereof, more particularly in the field of ...
NEW Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
Yeastern Biotech Co., Ltd
June 22, 2017 - N°20170173017

Or a salt form thereof. The compound of formula (i) has alk and fak inhibitory activity, and may be used to treat proliferative disorders.
NEW Antimitotic amides for the treatment of cancer and proliferative disorders
Frost Biologic, Inc.
June 22, 2017 - N°20170172984

Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of formula i where ar, r5, r6, r8, r9, r11, x1, and x2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.
NEW Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Diagnosis and treatment of viral diseases
Enzo Biochem, Inc.
June 15, 2017 - N°20170168053

This disclosure relates to methods of diagnosing a viral disease such as idiopathic pulmonary fibrosis, castleman's disease, a lymphoma, a thymoma or a sarcoma in a patient by identifying one or more virus-specific elements such as a nucleic acid or a viral protein or a patient antibody to a virus-specific element, as well as to kits for diagnosing the viral ...
O-glcnac transferase (ogt) inhibitors and uses thereof
The United States Of America, As Represented By The Secretary, Department Of Health And Human
June 15, 2017 - N°20170166558

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e. G., cancers), autoimmune diseases, and inflammatory diseases.
Functionalised and substituted indoles as anti-cancer agents
Novogen Limited
June 15, 2017 - N°20170166555

The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a proliferative disease, preferably cancer, using compounds of the invention.
Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
Novartis Ag
June 15, 2017 - N°20170165246

A pharmaceutical combination comprising: (a) an alpha-isoform specific phosphatidylinositol-3-kinase inhibitor (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) an mtor inhibitor and (c) exemestane or any pharmaceutically acceptable salt thereof, particularly for use in the treatment or prevention of a proliferative disease; uses of ...
Pharmaceutical compositions for the treatment of hyper-proliferative disorders
Bayer Healthcare, Llc
June 15, 2017 - N°20170165243

This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of formula i below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula i is as follows:
Immunoregulation by anti-ilts antibodies and ilts-binding antibody fragments
Merck Sharp & Dohme Corp.
June 08, 2017 - N°20170158765

Disclosed herein are methods of using anti-ilt5 antibodies and ilt5-binding fragments thereof to induce an immunostimulatory effect in a t cell when such a t cell is contacted with an antigen presenting cell (apc) that has been previously contacted with the anti-ilt5 antibody or ilt5-binding fragment. Also disclosed herein are methods of using anti-ilt5 antibodies and ilt5-binding ...
Proliferative Patent Pack
Download 369+ patent application PDFs
Proliferative Patent Applications
Download 369+ Proliferative-related PDFs
For professional research & prior art discovery
inventor
  • 369+ full patent PDF documents of Proliferative-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Multivalent ras binding compounds
Kyras Therapeutics, Inc.
June 08, 2017 - N°20170158702

Described herein are compounds that modulate ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using ...
Protein kinase inhibitors
Pharmascience Inc.
June 08, 2017 - N°20170158697

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, ...
Atx modulating agents
Biogen Ma Inc.
June 08, 2017 - N°20170158687

Disclosed are bicyclic aryl compounds of formula (i), that can modulate the activity of the autotaxin (atx) enzyme. This invention further relates to compounds that are atx inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
Functionalised and substituted carbazoles as anti-cancer agents
Novogen Ltd.
June 08, 2017 - N°20170158636

The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.
Substituted biaryl sulfonamides and the use thereof
Novomedix, Llc
June 08, 2017 - N°20170158627

Provided herein are substituted biaryl sulfonamide compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate initiation of protein translation. In one embodiment, the compounds provided ...
Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
Esperance Pharmaceuticals, Inc.
June 08, 2017 - N°20170157199

The invention relates to conjugates that bind to her2/neu, methods of using conjugates that bind to her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express her2/neu.
Oncolytic virus for expression of immune checkpoint modulators
Transgene S.a.
June 08, 2017 - N°20170157188

The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
Compositions and methods for disease treatment using nanoparticle delivered compounds
The Regents Of The University Of Michigan
June 08, 2017 - N°20170157149

Provided herein are compositions and methods for the treatment of diseases, such as hyperproliferative diseases, employing compounds formulated for pharmaceutical and research use via nanoparticles.
Loading